139 related articles for article (PubMed ID: 11295426)
61. Synthesis of specific SPECT-radiopharmaceutical for tumor imaging based on methionine: 99mTc-DTPA-bis(methionine).
Hazari PP; Shukla G; Goel V; Chuttani K; Kumar N; Sharma R; Mishra AK
Bioconjug Chem; 2010 Feb; 21(2):229-39. PubMed ID: 20108938
[TBL] [Abstract][Full Text] [Related]
62. Synthesis and comparative assessment of a labeled RGD peptide bearing two different ⁹⁹mTc-tricarbonyl chelators for potential use as targeted radiopharmaceutical.
Psimadas D; Fani M; Gourni E; Loudos G; Xanthopoulos S; Zikos C; Bouziotis P; Varvarigou AD
Bioorg Med Chem; 2012 Apr; 20(8):2549-57. PubMed ID: 22445386
[TBL] [Abstract][Full Text] [Related]
63. 99mTc-labeled RGD-BBN peptide for small-animal SPECT/CT of lung carcinoma.
Liu Z; Huang J; Dong C; Cui L; Jin X; Jia B; Zhu Z; Li F; Wang F
Mol Pharm; 2012 May; 9(5):1409-17. PubMed ID: 22452411
[TBL] [Abstract][Full Text] [Related]
64. Evaluation of
Shah SQ; Mahmood S
Cancer Biother Radiopharm; 2018 Apr; 33(3):96-102. PubMed ID: 29634355
[No Abstract] [Full Text] [Related]
65. Two peptide receptor ligands (99m)Tc-EDDA/HYNIC-Tyr(3)-octreotide and (99m)Tc-EDDA/HYNIC-(D)Glu-octagastrin for scintigraphy of medullary thyroid carcinoma.
Kosowicz J; Mikołajczak R; Czepczyński R; Ziemnicka K; Gryczyńska M; Sowiński J
Cancer Biother Radiopharm; 2007 Oct; 22(5):613-28. PubMed ID: 17979564
[TBL] [Abstract][Full Text] [Related]
66. Technetium-99m labeled to human immunoglobulin G through the nicotinyl hydrazine derivative: a clinical study.
Dams ET; Oyen WJ; Boerman OC; Claessens RA; Wymenga AB; van der Meer JW; Corstens FH
J Nucl Med; 1998 Jan; 39(1):119-24. PubMed ID: 9443750
[TBL] [Abstract][Full Text] [Related]
67. Pre-clinical evaluation of a new indirectly labeled ⁹⁹mTc-6-hydrazinopyridine-3-carboxylic acid (HYNIC)-depreotide with HYNIC as bifunctional chelator.
Yu F; Lü ML; Zhang XP; Fu D; Hou M; Cai HD; Li D; Wang J; Yuan XY; Lü ZW; Dong F
Chin Med J (Engl); 2012 Jul; 125(14):2538-42. PubMed ID: 22882936
[TBL] [Abstract][Full Text] [Related]
68. Comparison of in vitro and in vivo properties of [99mTc]cRGD peptides labeled using different novel Tc-cores.
Decristoforo C; Santos I; Pietzsch HJ; Kuenstler JU; Duatti A; Smith CJ; Rey A; Alberto R; Von Guggenberg E; Haubner R
Q J Nucl Med Mol Imaging; 2007 Mar; 51(1):33-41. PubMed ID: 17372571
[TBL] [Abstract][Full Text] [Related]
69. Evaluation of 99mTc-MAG3-annexin V: influence of the chelate on in vitro and in vivo properties in mice.
Vanderheyden JL; Liu G; He J; Patel B; Tait JF; Hnatowich DJ
Nucl Med Biol; 2006 Jan; 33(1):135-44. PubMed ID: 16459269
[TBL] [Abstract][Full Text] [Related]
70. Kinetics of 99mTc-labeled interleukin-8 in experimental inflammation and infection.
Rennen HJ; Boerman OC; Oyen WJ; Corstens FH
J Nucl Med; 2003 Sep; 44(9):1502-9. PubMed ID: 12960199
[TBL] [Abstract][Full Text] [Related]
71. Synthesis and biological evaluation of novel (99m)Tc-labelled bisphosphonates as superior bone imaging agents.
Qiu L; Cheng W; Lin J; Luo S; Xue L; Pan J
Molecules; 2011 Jul; 16(8):6165-78. PubMed ID: 21788926
[TBL] [Abstract][Full Text] [Related]
72. Synthesis and evaluation of the (99m)tc-complexes of L-cysteine acetyldiglycine (a hybrid of MAG3 and L,L-EC) and of L-beta-homocysteine acetyldiglycine.
Mang'era K; Vanbilloen H; Cleynhens B; de Groot T ; Bormans G; Verbruggen A; Verbeke K
Nucl Med Biol; 2000 Nov; 27(8):781-9. PubMed ID: 11150711
[TBL] [Abstract][Full Text] [Related]
73. Reduction of background activity through radiolabeling of antifibrin Fab' with 99mTc-dextran.
Line BR; Weber PB; Lukasiewicz R; Dansereau RN
J Nucl Med; 2000 Jul; 41(7):1264-70. PubMed ID: 10914920
[TBL] [Abstract][Full Text] [Related]
74. Tumor uptake of the RGD dimeric probe (99m)Tc-G3-2P4-RGD2 is correlated with integrin αvβ3 expressed on both tumor cells and neovasculature.
Liu Z; Jia B; Shi J; Jin X; Zhao H; Li F; Liu S; Wang F
Bioconjug Chem; 2010 Mar; 21(3):548-55. PubMed ID: 20184307
[TBL] [Abstract][Full Text] [Related]
75. The effect of molecular weight on nonspecific accumulation of (99m)T-labeled proteins in inflammatory foci.
Rennen HJ; Makarewicz J; Oyen WJ; Laverman P; Corstens FH; Boerman OC
Nucl Med Biol; 2001 May; 28(4):401-8. PubMed ID: 11395313
[TBL] [Abstract][Full Text] [Related]
76. 99m-Technetium-labelled peptide-HYNIC conjugates: effects of lipophilicity and stability on biodistribution.
Decristoforo C; Mather SJ
Nucl Med Biol; 1999 May; 26(4):389-96. PubMed ID: 10382842
[TBL] [Abstract][Full Text] [Related]
77. PEGylated and Non-PEGylated TCP-1 Probes for Imaging of Colorectal Cancer.
Liu Z; Gray BD; Barber C; Wan L; Furenlid LR; Liang R; Li Z; Woolfenden JM; Pak KY; Martin DR
Mol Imaging Biol; 2023 Feb; 25(1):133-143. PubMed ID: 34845659
[TBL] [Abstract][Full Text] [Related]
78. Biodistribution and renal excretion of isomers of the cationic tracer, (99m)Tc diaminocyclohexane (DACH): biodistribution of cationic renal tracers.
Taylor A; Hansen L; Marzilli LG
Nucl Med Biol; 2001 Apr; 28(3):299-302. PubMed ID: 11323241
[TBL] [Abstract][Full Text] [Related]
79. Preparation of (99m)Tc-C(60)(OH)(x) and its biodistribution studies.
Qingnuan L; yan X; Xiaodong Z; Ruili L; qieqie D; Xiaoguang S; Shaoliang C; Wenxin L
Nucl Med Biol; 2002 Aug; 29(6):707-10. PubMed ID: 12234597
[TBL] [Abstract][Full Text] [Related]
80. Labeling and Biological Evaluation of (99m)Tc-HYNIC-Trastuzumab as a Potential Radiopharmaceutical for In Vivo Evaluation of HER2 Expression in Breast Cancer.
Calzada V; Garcia F; Fernández M; Porcal W; Quinn T; Alonso O; Gambini JP; Cabral P
World J Nucl Med; 2013 Jan; 12(1):27-32. PubMed ID: 23961253
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
